Gwyneth Paltrow expresses admiration for the benefits of medicinal mushrooms, but event planners of psychedelic gatherings find it challenging to cater to a diverse audience. New studies shed light on the positive impact of psilocybin use in reducing psychological distress, while some researchers suggest microdosing could hold promise for addressing ADHD.
Individuals with Adverse Childhood Experiences May Experience Reduced Psychological Distress When Using Psilocybin Mushrooms
A recent study published in the Journal of Psychoactive Drugs has found a correlation between the use of psilocybin and a decrease in distress among individuals who have experienced childhood adversity. This supports the existing research that suggests magic mushrooms have the potential to alleviate symptoms of depression, anxiety, and suicidal ideation.
The study focused on adverse childhood experiences, such as abuse, neglect, and exposure to violence, and collected data on the participants’ demographics and history of psilocybin use. The participants completed assessments to evaluate their childhood trauma experiences and psychological distress levels.
The results indicate that recent psilocybin use, within the past three months, was with lower levels of psychological distress, particularly benefiting those with a history of childhood adversity. Additionally, psilocybin users highlight positive opinions about the substance’s benefits and safety, often using it as a tool for self-help in addressing mental health challenges.
New Study Suggests Combining Psychedelic Microdoses with ADHD Medication Could Work
Despite some researchers challenging the practice of microdosing and attributing its benefits to the placebo effect, many individuals have turned to this method to alleviate symptoms of ADHD. A recent study on real-world psychedelic microdosing for ADHD provides interesting insights that could potentially revolutionize how we treat this disorder.
Published in the Frontiers in Psychiatry Journal, the microdosing study gathered data from 233 individuals through an online prospective naturalistic design. A significant portion of the participants had ADHD, while the remaining had severe symptoms. Around one-third of the subjects took daily medication for ADHD, which worsens anxiety and stress.
Around 78% of the participants microdosed psilocybin, with an average dose of 722 mg. It’s worth noting that this average dose does not align with the generally accepted microdosing range of 0.1 to 0.3 grams of psilocybin. We can only speculate on the factors that may have contributed to this significant difference. Psychedelic Spotlight suggests that there may have been an interaction with the medication or a developed tolerance.
According to the study findings, microdosers with ADHD experienced increased mindfulness, heightened awareness, reduced judgment of inner experiences, and decreased neuroticism or emotional instability after four weeks. Interestingly, participants who combined microdosing with conventional ADHD medication showed similar improvements in mindfulness, challenging the idea that pharmaceuticals are the sole solution for managing ADHD.
Overall, microdosing appears to enhance mindfulness and reduce symptoms of neuroticism and emotional instability in adults with ADHD. These improvements remain evident even when microdosing is together with traditional prescription medications. The study’s implications suggest that incorporating both psychedelic benefits and pharmaceutical reliability could offer a comprehensive ADHD protocol.
The Deadline for Californians to Provide Feedback on the Revised Psychedelics Ballot Proposal is Approaching on Monday
The deadline for Californians to submit comments on the revised psychedelic ballot measure is Monday. If the measure is passed, individuals who are 21 and older will be allowed to possess and use psychedelics for medical, therapeutic, and spiritual purposes with a doctor’s recommendation. Additionally, adults will have the right to grow entheogenic plants and fungi on their private property.
The Psychedelic Wellness and Healing Initiative of 2024 was filed with state officials last month, and organizers have until November 27 to gather public comments for submission to the state attorney general. Dave Hodges, the lead campaign organizer and founder of the Church of Ambrosia in Oakland, stated that the final update will be completed by December 1.
Massachusetts Advocates Strive to Replace Psychedelic Ballot Measure, Uncover Voter Manipulation by D.C. PAC
According to Bay Staters for Natural Medicines, funded by New Approach PAC, there have been instances of misleading voters by canvassers supporting a psilocybin ballot question campaign in Massachusetts. Videos taken by Bay Staters reveal canvassers providing false information to voters in order to gain signatures for the petition.
The footage shows paid canvassers falsely claiming to be unpaid volunteers, misrepresenting the law as applicable only to medical use, stating that insurance will cover the costs, and asserting that the ballot measure is the sole option for legalizing psychedelic services. Furthermore, the canvassers were unsure about the organization that had hired them.
Bay Staters for Natural Medicine aims to collaborate with legislators to propose an alternative policy due to concerns about potential high costs and the impact on accessibility and affordability.
Actress Gwyneth Paltrow Praises Psychedelics for their Potential As Mental Health Treatments
During an interview with People magazine, the renowned actress and founder of Goop voiced her support for the use of psychedelics in addressing mental health conditions. She specifically praised the therapeutic properties of psilocybin mushrooms, stating that she believes psychedelics are the next significant frontier in the field of mental health.
This is not a new interest for Paltrow, as evidenced by her docuseries “The Goop Lab”. In the series’ inaugural episode titled “The Healing Trip”, she and her team traveled to Jamaica to legally explore the potential of medicinal mushrooms. Paltrow also conducted an interview with Mark Haden, formerly the Executive Director of MAPS Canada and currently a member of Clearmind Medicine’s Advisory Board, a biotech company involved in investigating MEAI for the treatment of Alcohol Use Disorder. This episode offers valuable insights into the research on psychedelics and their therapeutic applications.
Regardless of personal opinion on Paltrow, it is worth noting that she was among the first celebrities to openly discuss the healing potential of psychedelics, challenging the undue fear. So, regardless of her unconventional ventures like creating candles with unique fragrances, such as the infamous vagina-scented candle, her stance on psychedelics remains significant.
So… Can You Provide an Update on The Situation Involving the Attendee Who Was Expelled from the 2023 Wonderland Conference?
Over the past few years, psychedelic conferences have made significant progress in destigmatizing psychedelics by bringing together various stakeholders. However, these conferences have also faced some challenges. In 2022, Microdose excluded certain journalists from their Wonderland event, leading to controversies on Twitter and in podcasts.
Similarly, during Psychedelic Science 2023, a group of indigenous people interrupted Rick Doblin’s speech, demanding inclusion in the psychedelic discourse. Recently, at the Wonderland Miami Conference, an attendee was expelled due to his complaints, sparking a conversation on LinkedIn about accountability and event management.
The expelled attendee, Parham Albadvi, was not happy with logistical issues and this caused him to have unpleasant exchanges with event organizers. Albadvi highlights that he was racially profiled as a Middle Eastern individual and forcefully removed by black bodyguards in front of a mostly white audience. Microdose, in response, stated that Albadvi’s expulsion was due to violating the event’s code of conduct by being overly aggressive and using offensive language towards a female staff member.
A public exchange between Albadvi and Microdose’s senior editor, Jason Najum, who shares a Middle Eastern background, followed, with Najum refuting claims of racism while Microdose’s CEO highlights that the expulsion was according to behavior rather than race.
Organizing psychedelic conferences appears to be more challenging than other events for various reasons. It could be due to attendees and organizers having insufficient sleep, which may affect emotional responses, or the difficulty of meeting the diverse community’s demands. Given the nature of the psychedelics space, it is likely that more incidents will occur in the future.